Veracity Capital LLC Has $372,000 Stock Position in Danaher Co. (NYSE:DHR)

Veracity Capital LLC grew its stake in shares of Danaher Co. (NYSE:DHR) by 4.9% during the 1st quarter, Holdings Channel reports. The firm owned 1,490 shares of the conglomerate’s stock after buying an additional 69 shares during the period. Veracity Capital LLC’s holdings in Danaher were worth $372,000 as of its most recent SEC filing.

Several other institutional investors have also recently made changes to their positions in the stock. Wellington Management Group LLP increased its position in shares of Danaher by 12.0% during the 4th quarter. Wellington Management Group LLP now owns 27,928,442 shares of the conglomerate’s stock worth $6,460,966,000 after purchasing an additional 2,998,161 shares during the last quarter. Price T Rowe Associates Inc. MD increased its holdings in shares of Danaher by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 16,757,558 shares of the conglomerate’s stock worth $3,876,694,000 after acquiring an additional 1,619,586 shares during the last quarter. Capital International Investors increased its holdings in shares of Danaher by 9.1% during the 4th quarter. Capital International Investors now owns 15,956,519 shares of the conglomerate’s stock worth $3,691,735,000 after acquiring an additional 1,334,781 shares during the last quarter. Norges Bank acquired a new position in shares of Danaher during the 4th quarter worth approximately $1,752,382,000. Finally, Franklin Resources Inc. increased its holdings in shares of Danaher by 6.4% during the 4th quarter. Franklin Resources Inc. now owns 6,620,170 shares of the conglomerate’s stock worth $1,531,510,000 after acquiring an additional 395,498 shares during the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on DHR shares. Citigroup boosted their target price on Danaher from $280.00 to $290.00 and gave the stock a “buy” rating in a report on Wednesday, April 24th. StockNews.com lowered Danaher from a “buy” rating to a “hold” rating in a report on Tuesday, June 25th. Evercore ISI decreased their price objective on Danaher from $266.00 to $260.00 and set an “outperform” rating on the stock in a report on Tuesday. HSBC raised Danaher from a “hold” rating to a “buy” rating and upped their price objective for the company from $250.00 to $280.00 in a report on Wednesday, April 17th. Finally, Bank of America upped their price objective on Danaher from $258.00 to $270.00 and gave the company a “neutral” rating in a report on Wednesday, April 24th. Six research analysts have rated the stock with a hold rating and eleven have given a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $268.67.

Danaher Price Performance

Shares of DHR stock opened at $241.23 on Friday. The company has a quick ratio of 1.51, a current ratio of 1.85 and a debt-to-equity ratio of 0.31. Danaher Co. has a twelve month low of $182.09 and a twelve month high of $269.11. The company has a market cap of $178.68 billion, a P/E ratio of 40.68, a P/E/G ratio of 3.67 and a beta of 0.83. The business has a fifty day simple moving average of $255.56 and a 200 day simple moving average of $246.86.

Danaher (NYSE:DHR) last announced its quarterly earnings data on Tuesday, April 23rd. The conglomerate reported $1.92 earnings per share for the quarter, topping the consensus estimate of $1.72 by $0.20. Danaher had a return on equity of 11.43% and a net margin of 16.78%. The business had revenue of $5.80 billion during the quarter, compared to the consensus estimate of $5.62 billion. During the same period in the prior year, the company earned $2.36 EPS. Danaher’s revenue for the quarter was down 2.6% on a year-over-year basis. On average, sell-side analysts forecast that Danaher Co. will post 7.63 EPS for the current fiscal year.

Danaher Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Friday, July 26th. Shareholders of record on Friday, June 28th will be given a $0.27 dividend. The ex-dividend date is Friday, June 28th. This represents a $1.08 annualized dividend and a yield of 0.45%. Danaher’s dividend payout ratio is presently 18.31%.

Insider Buying and Selling at Danaher

In other Danaher news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Danaher news, CEO Rainer Blair sold 9,005 shares of the stock in a transaction dated Thursday, May 16th. The stock was sold at an average price of $265.00, for a total value of $2,386,325.00. Following the completion of the transaction, the chief executive officer now directly owns 106,990 shares in the company, valued at $28,352,350. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Alan G. Spoon sold 708 shares of the stock in a transaction dated Thursday, May 2nd. The shares were sold at an average price of $243.58, for a total value of $172,454.64. Following the completion of the transaction, the director now owns 116,202 shares of the company’s stock, valued at $28,304,483.16. The disclosure for this sale can be found here. Over the last three months, insiders sold 148,783 shares of company stock worth $37,536,717. 10.90% of the stock is currently owned by insiders.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.